Illinois ADVANCE

Newsletter

February 2025

BREATHE EASY THIS WINTER: ADVANCES IN ASTHMA MANAGEMENT

Midwest winters can be especially challenging for patients with asthma. But there's good news! Exciting advancements in asthma management, including the proven effectiveness of SMART therapy in clinical trials, are changing the landscape of care.

The Illinois Pharmacists Association (IPhA) and Illinois ADVANCE are partnering to bring you comprehensive education on these important updates. By working together and providing accessible educational resources, we can significantly improve patient outcomes.

Join us for

- **Informative Webinars:** Deep dive into the latest updates in asthma management, including SMART therapy. [Click here to access the IPhA education on SMART therapy.]
- **Interactive Academic Detailing Sessions:** Engage with our clinical pharmacists and gain practical insights you can use in your practice. [Click here to sign up for a session with us.]
- **Bonus:** Earn free Continuing Education (CE) credits while you learn!

Let us empower you with the knowledge you need to provide the best possible care for your patients. We're here to support you on your educational journey in healthcare.

ILLINOIS ADVANCE: YOUR PARTNER IN CARDIOVASCULAR HEALTH THIS FEBRUARY

February is American Heart Month! Cardiovascular disease remains a leading cause of death in the United States, with a staggering statistic of a myocardial infarction occurring every 40 seconds. The American Heart Association emphasizes the importance of managing key risk factors, including blood pressure, blood sugar, and smoking! Sign up for a visit with a clinical pharmacist at Illinois ADVANCE and stay up to date on hypertension, diabetes, and smoking cessation!

SUZETRIGINE (JOURNAVX): A BREAKTHROUGH, FIRST-IN-CLASS APPROACH TO ACUTE PAIN RELIEF

Suzetrigine (Journavx), a novel analgesic, indicated for the treatment of moderate to severe acute pain in adults, works by selectively targeting the $Na_v1.8$ voltage-gated sodium channel. This channel is preferentially expressed in peripheral sensory neurons, particularly dorsal root ganglion neurons, and is crucial for pain signal generation and propagation. Suzetrigine offers a new approach to pain management without the risk of respiratory depression, addiction, or gastrointestinal bleeding.

Source: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219209s000lbl.pdf